These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32702381)

  • 1. Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression.
    Bi Y; Ren D; Guo Z; Ma G; Xu F; Chen Z; An L; Zhang N; Ji L; Yuan F; Liu L; Hou B; Yang F; Yu S; Yi Z; Xu Y; He L; Sun X; Dong Z; Wu S; Zhao L; Cai C; Li X; Yu T; Shi Y; He G
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110036. PubMed ID: 32702381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum brain-derived neurotrophic factor, Val66Met polymorphism and open-label SSRI treatment response in Major Depressive Disorder.
    Smit AJT; Wu GWY; Rampersaud R; Reus VI; Wolkowitz OM; Mellon SH
    Psychoneuroendocrinology; 2024 Jul; 165():107045. PubMed ID: 38636352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
    Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
    Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
    J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model.
    Smits KM; Smits LJ; Schouten JS; Peeters FP; Prins MH
    Clin Ther; 2007 Apr; 29(4):691-702. PubMed ID: 17617292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients.
    Colle R; Gressier F; Verstuyft C; Deflesselle E; Lépine JP; Ferreri F; Hardy P; Guilloux JP; Petit AC; Fève B; Falissard B; Becquemont L; Corruble E
    J Affect Disord; 2015 Apr; 175():233-40. PubMed ID: 25658497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
    Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
    J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
    Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK
    JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response.
    Yu YW; Tsai SJ; Hong CJ; Chen TJ; Chen MC; Yang CW
    Neuropsychopharmacology; 2005 Sep; 30(9):1719-23. PubMed ID: 15956990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
    Knorr UB
    Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder.
    Lin E; Chen PS; Chang HH; Gean PW; Tsai HC; Yang YK; Lu RB
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1167-72. PubMed ID: 19560507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response.
    Xu Z; Zhang Z; Shi Y; Pu M; Yuan Y; Zhang X; Li L
    J Affect Disord; 2011 Sep; 133(1-2):165-73. PubMed ID: 21680027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder: Sequencing Analysis of SLC6A4.
    Nonen S; Kato M; Takekita Y; Wakeno M; Sakai S; Serretti A; Kinoshita T
    J Clin Psychopharmacol; 2016 Feb; 36(1):27-31. PubMed ID: 26674707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin Transporter Gene Promoter Hypomethylation as a Predictor of Antidepressant Treatment Response in Major Depression: A Replication Study.
    Schiele MA; Zwanzger P; Schwarte K; Arolt V; Baune BT; Domschke K
    Int J Neuropsychopharmacol; 2021 Mar; 24(3):191-199. PubMed ID: 33125470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.
    Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A
    J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
    Tundo A; de Filippis R; Proietti L
    World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
    Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
    Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder.
    Tsai SJ; Liou YJ; Hong CJ; Yu YW; Chen TJ
    Pharmacogenomics J; 2008 Dec; 8(6):384-90. PubMed ID: 18195729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables.
    Gudayol-Ferré E; Guàrdia-Olmos J; Peró-Cebollero M; Herrera-Guzmán I; Camarena B; Cortés-Penagos C; Herrera-Abarca JE; Martínez-Medina P
    J Affect Disord; 2013 Sep; 150(3):1082-90. PubMed ID: 23787408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.